Elsevier

Brain Research

Volume 649, Issues 1–2, 27 June 1994, Pages 217-224
Brain Research

The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum

https://doi.org/10.1016/0006-8993(94)91067-7Get rights and content

Abstract

Administration of methamphetamine (MA) induces degeneration of dopaminergic nerve terminals and astrogliosis, such as hypertrophy and an increase in apparent number, in the neostriatum. In this experiment adult rats were treated with MA (10 mg/kg, i.p.) 4 times in one day at 2 h intervals. Amfonelic acid (AFA), a dopamine reuptake inhibitor, was administered (20 mg/kg, i.p.) at the same time the last MA dose was given. Three days later, dopaminergic terminals and astrocytes were examined immunohistochemically and the contents of striatal dopamine and its metabolites were analyzed by HPLC. The results showed that MA-induced the typical depletion of dopaminergic terminals, reduction of dopamine content and astrogliosis in the neostriatum. AFA treatment completely prevented the effects of MA on the dopaminergic system, both morphologically and biochemically. However, the reaction of astrocytes remained in the region where the most severe depletion dopaminergic terminals was seen in MA treated animals (ventral-lateral portion of neostriatum). The results support the concept that the dopamine transporter is involved in MA-induced dopaminergic nerve terminal degeneration. The results also indicate that blocking the dopamine transporter cannot completely prevent the reaction of astrocytes in the neostriatum, which indicates that the astrocytic reaction can be induced by factors other than degeneration of dopaminergic terminals in this region. Based on these and other data, it is hypothesized that MA may cause degeneration of corticostriatal glutamate pathways and this effect may be responsible for the astrogliosis in MA-AFA treated animals.

Reference (39)

Cited by (71)

  • Parkin-deficient rats are resistant to neurotoxicity of chronic high-dose methamphetamine

    2021, Experimental Neurology
    Citation Excerpt :

    We found that PKO rats are somewhat resistant to METH neurotoxicity in the striatum. At the molecular level, METH neurotoxicity to DAergic and 5-HTergic terminals in the striatum is manifested by persistent (lasting after METH cessation) reductions in all DAergic and 5-HTergic markers (e.g. DA, 5-HT and their metabolites) (Broening et al., 1997; Harvey et al., 2000; Preston et al., 1985; Sonsalla et al., 1986; Wagner et al., 1980), morphological and structural abnormalities (Lorez, 1981; Ricaurte et al., 1982; Sharma and Kiyatkin, 2009) as well as microglial activation and gliosis (Pu et al., 1994; Thomas et al., 2004). In rodents, binge METH exposure typically results in more severe or longer-lasting effects than a chronic exposure of comparable cumulative dose (Keller et al., 2011; Kesby et al., 2018; Moszczynska et al., 1998), suggesting development of tolerance to METH toxic effects.

  • Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis

    2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • A peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity

    2017, Experimental Neurology
    Citation Excerpt :

    D2R and DAT, two important presynaptic proteins that regulate dopamine concentration in the synapse, have been found to play important roles in dopamine neurotoxicity. D2R antagonists and DAT blockers were shown to attenuate METH-induced degeneration of dopaminergic terminals thus implicating both D2R as well as DAT in mediating the neurotoxicity of the drug (Albers and Sonsalla, 1995; Eisch and Marshall, 1998; Hadlock et al., 2010; Marek et al., 1990; Pu et al., 1994). METH is initially taken up to dopaminergic terminals via DAT.

  • Mephedrone: An Overview of Its Neurotoxic Potential

    2016, Neuropathology of Drug Addictions and Substance Misuse
View all citing articles on Scopus
**

Current address: the Neuropharmacological Drug Products Branch, Center for Drug Safety, US Food and Drug Administration; 5600 Fishers Lane, Rockville, MD 20857, USA.

View full text